Questions about the three peptides
A few of the recurring questions are quite precise. The answers are easier to trust when they stay that way.
Is retatrutide FDA approved?
Retatrutide is investigational, remains in phase 3 trials and has not been approved by the FDA or any other regulator. The clinical programme review discusses the published early trials and ongoing development. The substantial weight-loss result is a trial finding, with approval still pending.
How does retatrutide work?
It activates GIP, GLP-1 and glucagon receptors. The receptor structures and cell-based signalling experiments show that its activity is uneven across those targets. The retatrutide page follows that combination through weight, glucose, liver fat and the pulse finding. I rate retatrutide’s clinical combination above a bare count of receptors.
How is retatrutide prepared?
There is no approved formulation or preparation standard for non-trial retatrutide. In the clinical work, it was an investigational product administered under trial conditions. Material from research channels has unverified identity, concentration, purity and sterility. Savvy Peptides provides no mixing or administration instructions.
BPC-157 versus growth hormone
BPC-157 is a synthetic 15-amino-acid gastric-protein fragment. It has been studied for tissue repair, and cell experiments involving growth-hormone receptors can be a source of confusion. Those experiments describe signalling in cultured tendon cells. The musculoskeletal review leaves human recovery claims dependent on a very limited evidence base; it does not establish BPC-157 as a treatment for raising growth hormone.
Does BPC-157 work immediately?
Human evidence has not established a reliable onset of therapeutic effect. The pharmacokinetic study in rats and beagle dogs reported an elimination half-life under 30 minutes. That measures how quickly the compound leaves circulation in those animals. A recovery timescale in people would require a different experiment. The 2025 review found large, rigorous human trials lacking.
BPC-157 liver safety
The intravenous pilot in two adults observed no measurable changes in liver biomarkers, alongside the other safety measures it checked. That tiny, uncontrolled experience cannot establish long-term liver safety or exclude less common harm. The BPC-157 liver-safety claim asks more of that pilot than its two participants can supply.
What is thymosin alpha-1 used for?
The comprehensive review describes international use, including chronic viral hepatitis, and approval in more than 35 countries. A separate oncology review considers it as an adjunct to chemotherapy and immunotherapy. It has no United States marketing authorisation. Its large sepsis trial found no significant 28-day mortality benefit, which deserves specific mention whenever immune support is discussed.